© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2012

# Development of Multiple ELISAs for the Detection of Antibodies against Classical Swine Fever Virus in Pig Sera\*

Zhen-hua Yang, Ling Li and Zi-shu Pan\*\*

(State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China)

**Abstract:** The major immunogenic proteins (E<sup>rns</sup>, E2 and NS3) of classical swine fever virus (CSFV) (Shimen strain) were expressed in *E. coli* and purified by affinity chromatography. The recombinant antigens were applied to develop multiple enzyme-linked immunosorbent assays (ELISAs) for the detection of specific antibodies in pig sera. Optimum cut-off values were determined by receiver operating characteristic (ROC) analysis after testing 201 sera of vaccinated pigs and 64 negative sera of unvaccinated piglets. The multiple ELISAs were validated with 265 pig sera yielding high sensitivity and specificity in comparison with the virus neutralization results. The results demonstrated that multiple ELISAs can be a valuable tool for the detection of CSFV infection and serological surveys in CSFV-free countries or for the evaluation of the antibody responses in pigs induced by a live attenuated C-strain vaccination.

Key words: Classical swine fever virus; Recombinant antigens; ELISA

Classical swine fever (CSF) is a highly contagious disease of pigs, caused by infection with classical swine fever virus (CSFV), leading to significant economic losses worldwide<sup>[7, 17, 18, 24]</sup>. CSF disease control is primarily dependent on preventive vaccination and the conventional attenuated live C-strain vaccine is considered as one of the most effective preventive vaccines for the control of CSF

and has been widely used in many countries, including China.

CSFV, a member of the genus *Pestivirus* within the family *Flaviviridae*, contains a genome of approximately 12.5kb with a single large open reading frame (ORF). The ORF is translated to a polyprotein that is processed into 12 mature proteins by viral and host cell proteases<sup>[19, 27]</sup>. Among the CSFV proteins, the structural proteins E<sup>rns</sup>, E2, and the nonstructural protein NS3 are the three immunogens inducing detectable antibodies<sup>[12, 22, 23]</sup>. Specific anti-E2 is a major virus neutralizing antibody<sup>[9, 11, 29]</sup> whereas antibodies against E<sup>rns</sup> and NS3 have only low neutralizing activity, or none at all<sup>[11, 31]</sup>.

Received: 2011-10-12, Accepted: 2011-12-15

\*\* Corresponding author.

Phone: +86-27-68752833, Fax: +86-27-68754592,

E-mail: zspan@whu.edu.cn



<sup>\*</sup> Foundation items: the National Natural Science Foundation of China (30771597); the Key Project of Science and Technology of Wuhan (200720422141).

Detection of specific antibodies is widely used for diagnosis and surveillance of viral diseases. The conventional methods for the detection of antibodies to CSFV are the virus neutralization assay and the enzyme-linked immunosorbent assay (ELISA)[5, 21, 26]. Regarded as a gold standard, the virus neutralization assay nevertheless has several limitations including a time-consuming, the requirement of cell culture, the need for live virus manipulation, and expensive and hampered standardization due to subjective plaque-reading. Furthermore, ELISA based on viral antigens of CSFV is disadvantageous because of low virus titer in tissue cultures and the complicated viral antigen preparation. Therefore, the ELISA based on recombinant E2 or E<sup>rns</sup> has been developed<sup>[3, 4, 13, 20, 22]</sup>. In the present study, multiple ELISAs based on the recombinant CSFV E<sup>rns</sup>, the truncated E2 (tE2) and NS3 were developed. Anti-E<sup>rns</sup>, anti-E2 and anti-NS3 antibody titers in sera of vaccinated pigs were then evaluated by the multiple ELISAs.

#### MATERIALS AND METHODS

#### Test sera

The serum panel consisted of vaccinated (n = 201) and unvaccinated pig sera (n = 64). Positive sera of pigs vaccinated with commercial attenuated vaccines

(the Chinese lapinized vaccine, C-strain) from 6 farms were kindly supplied by the Wuhan Center for Animal Disease Control. Positive serum samples in pigs vaccinated with an attenuated C-strain vaccine were collected at a 1, 3 or 5 month intervals post vaccination (p.v.), respectively. Negative sera were collected from 6-week-old unvaccinated piglets in 2 CSFV-free farms. Neutralization antibody titers in pig sera were tested by the virus neutralization assay.

### Cloning, expression and purification of the recombinant $E^{rns}$ , tE2 and NS3 proteins

To obtain the recombinant antigens, the full-length (fl)E<sup>rns</sup> (from position 1175 to 1855), the truncated E2 (tE2) (from 2441 to 2972nt), and flNS3 (from 5141 to 7189) gene fragments were amplified from a full-length infectious cDNA clone (pT7SM) of CSFV Shimen Strain<sup>[32]</sup>. Oligonucleotides employed to amplify E<sup>rns</sup>, tE2 and NS3 fragments are listed in table 1. E<sup>rns</sup> and NS3 fragments were cloned into pET-28α vectors (Novagen) with *Bam*H I and *Eco*R I or with *Bgl* II and *Sal* I, to generate pET/E<sup>rns</sup> and pET/NS3, respectively. Similarly, tE2 was cloned into pMAL-p2x (New England Biolabs) with *Bam*H I and *Hin*d III, to generate pMAL/tE2. All clones were confirmed by DNA sequencing.

Table 1. Oligonucleotides employed to amplify E<sup>rns</sup>, tE2 and NS3 coding regions

Oligonucleotides	Sequences
$E^{rns}f$	5'-GTT <u>GGATCC</u> GAAAATATAACTGAATGG-3'
$\mathrm{E}^{\mathrm{rns}}\mathbf{r}$	5'-AGG <u>GAATTC</u> GGCATAGGCACCAAACCAG-3'
tE2f	5' -TGA <u>GGATCC</u> GGCGGCGGCGGCAGCAGCCGTCTAGCCTGCAA-3'
tE2r	5' -ATGA <u>AAGCTT</u> ATAGATCTTCATTTTCCACTGTGGTG-3'
NS3f	5'-GGG <u>AGATCT</u> GGGCCTGCCGTTTGCAAG-3'
NS3r	5'-CCGTCGACTTATAGACCAACTACTTGTTTTAGTGCT-3'

Underlined sequences correspond to restriction sites used for cloning into the expression plasmid.



To express and purify E<sup>rns</sup>, tE2 or NS3 protein, the recombinant plasmid pET/E<sup>rns</sup>, pMAL/tE2 pET/NS3 was transformed in competent E. coli BL21 (DE3) CodonPlus cells (Stratagene, San Diego, CA). The E. coli cells harbouring pET/E<sup>rns</sup>, pMAL/tE2 or pET/NS3 were grown at 37 °C in LB medium containing antibiotics to an optical density of 0.6 at 600 with shaking. Isopropyl-1-thio-β-Dgalactopyranoside (IPTG) (Sigma-Aldrich, St Louis, Missouri, USA) was added to a final concentration of 0.5 mmol/L and the bacterial cells were grown for five additional hours at 30 °C, pelleted by centrifugation. The cells were resuspended in binding buffer (20 mmol/L imidazole, 500 mmol/L NaCl, 20 mmol/L Tris-HCl, pH 7.4 for E<sup>rns</sup> and NS3 purification or 10 mmol/L HEPES-KOH, 200 mmol/L NaCl, 1 mmol/L M EDTA, pH 7.4 for tE2 purification ) containing 1 mmol/L PMSF and lysozyme (100 µg/mL), incubated on ice for 30 min, followed by sonication. Cell debris was removed by centrifugation at 12,000 r/min for 30 min. For E<sup>rns</sup> and NS3 purification, the supernatant was added to the Ni-NTA agarose resin column (Amersham, USA). After incubation and washing, the E<sup>rns</sup> or NS3 was eluted with elution buffer (500 mmol/L imidazole, 500 mmol/L NaCl, 20 mmol/L Tris-HCl, pH 7.4). For tE2 purification, the supernatant was added into a column of amylose resin (Biolabs, New England). After washing, the tE2 was eluted with elution buffer (10 mmol/L HEPES-KOH, 200 mmol/L NaCl, 1 mmol/L EDTA, 10 mmol/L maltose, pH 7.4). Peak fractions were pooled and then dialyzed against a buffer containing 50 mmol/L Tris-HCl (pH 7.6), 150 mmol/L NaCl, and 20% glycerol. The purified proteins were analyzed by SDS-PAGE and Western blot. After concentration as previously described<sup>[32]</sup>, the proteins were divided into aliquots and stored at -80 °C.

#### **Indirect ELISA**

Independent ELISAs based on the recombinant E<sup>rns</sup>, tE2 or NS3 antigen were developed. Optimal concentration of each antigen as well as pig sera and anti-pig IgG conjugated with horseradish peroxidase (HRP) were determined by checkerboard titration.

96-well microtiter plates (Greiner, Germany) were coated with an optimal concentration of the purified antigens (0.2 µg/well for E<sup>rns</sup> and tE2; 0.3 µg /well for NS3). The coating antigens in 0.06 mmol/L carbonate buffer (pH9.6) were aliquoted into each well (100 μL/well) and incubated overnight (18-20 h) at 4 °C. After washing with phosphate-buffered saline containing 0.05% Tween-20 (PBST), the plates were blocked for 1 h at 37 °C with 100 µL/well of PBST containing 3% BSA (pH7.4). After several washes, 100 μL of diluted pig sera (1:200) in PBST was added to each well in duplicate and incubated for 1 h at 37 °C. After washing, the plates were incubated for 1 h at 37 °C with 100 μL/well of HRP-labeled anti-pig IgG (Sigma-Aldrich, St. Louis, MO, USA) diluted 1:5000 in PBST. Following several washes, plates were incubated for 10-30 min with 0.1 mL of 0.045% H<sub>2</sub>O<sub>2</sub> and 0.4 mg/mL of O-phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich) in phosphate-citrate buffer (0.1 mol/L citric acid, 0.2 mol/L sodium phosphate dibasic, pH 5.0). The reaction was stopped by adding 100 µL of 2 mmol/L H<sub>2</sub>SO<sub>4</sub> and the absorbance was measured at 492 nm using an ELISA reader (Multiskan MK3, Thermo, USA).

#### Virus neutralization assay

All pig sera employed in these assays were tested for the presence of virus neutralizing antibodies against CSFV as previously described<sup>[30]</sup>. Briefly,



2-fold serially diluted sera were incubated with equal volumes of 100 TCID<sub>50</sub> CSFV (Shimen strain) in a 96-well plate for 1 h and then the virus/serum mixture was replaced with fresh medium. After incubation in a humidified atmosphere containing 5% CO<sub>2</sub> for 3 days, the confluent monolayer was fixed with 50% methanol and 50% acetone at -20 °C for 1 h and extensively washed with PBST. A rabbit polyclonal anti-CSFV serum (1:500 dilution) was added and incubated for 1 h at 37 °C. Plates were washed and an FITC-conjugated goat anti-rabbit IgG (1:200 dilution) was added. The serum neutralization titers were recorded as the reciprocal of the highest serum dilution at which the fluorescence was 50% or less than that of the virus infected control well.

### Determination of cut-off values and variation coefficients

The cut-off value of each ELISA was determined by receiver operating characteristic (ROC) curve with default settings (software SPSS, version 15.0). Optical density (OD) values at 492 nm from a total of 201 pig sera of vaccinated pigs and 64 negative sera of unvaccinated piglets were analyzed by the ROC curves. Optimal cut-off values were determined by ROC analysis by comparing false negative (FN) and false positive (FP) rates for every possible cut-off. ROC curves were created by plotting the sensitivity (Sensitivity = TP / (TP + FN)) against 1-specificity (Specificity = TN / (FP + TN)) for different cut-off values of each ELISA. The intra- and inter-assay variation coefficients (VC) were estimated as previously described<sup>[2, 10]</sup>.

#### **RESULTS**

#### Purification and identification of recombinant E<sup>rns</sup>,

#### tE2 and NS3 proteins

The CSFV E<sup>rns</sup>, tE2 or NS3 was separately expressed in *E. coli* and purified by affinity chromatography. SDS-PAGE analysis showed that the recombinant E<sup>rns</sup>, tE2 and NS3 achieved high-purify and their sizes were 28 kDa, 62 kDa and 80 kDa, respectively (Fig. 1A). Western blotting identified that these proteins were reactive with specific anti-E2 monoclonal or anti-CSFV rabbit polyclonal antibody (Fig. 1B). The purified E<sup>rns</sup>, tE2 and NS3 were subsequently used as coating antigens for the ELISAs.

# Development of multiple ELISAs based on the $E^{rns}$ , tE2 and NS3 antigens

The results of checkerboard titration showed that the coating antigens at  $0.2 \mu g/well$  for  $E^{rms}$  and tE2 proteins, or at  $0.3 \mu g/well$  for NS3 gave the highest ratio  $OD_{492}$  values for positive sera to negative sera (P/N). Thus, the optimal coating antigens were set at  $0.2 \mu g/well$  for  $E^{rms}$  and tE2, or  $0.3 \mu g/well$  for NS3. The optimal dilution of pig sera and anti-pig IgG was 1:200 and 1:5000, respectively. In addition, PBST




Fig. 1. Purification and analysis of the recombinant E<sup>rns</sup>, tE2 and NS3 of CSFV in *E. coli*. A: The purified E<sup>rns</sup> (lane 1), tE2-MBP (lane 2) and NS3 (lane 3) proteins were analyzed by SDS-PAGE. B: Western blot analysis of the tE2-MBP (lane 1), E<sup>rns</sup> (lane 2) and NS3 (lane 3) proteins expressed in *E. coli* using anti-E2 monoclonal antibody or rabbit anti-CSFV polyclonal antibodies. MW, standards of molecular weight.



containing 1% BSA for serum dilution and 3% BSA for blocking gave the better P/N values.

### Validation of the ELISA-E<sup>rns</sup>, ELISA-E2 and ELISA-NS3

Once the final procedures were set up, the specificity and sensitivity of multiple ELISAs were evaluated through 201 positive sera of vaccinated pigs and 64 negative sera of unvaccinated piglets. The cut-off values were optimized by the ROC analyses of software SPSS (Version 15.0) by non-parametric methods at 95% accuracy level; areas under the ROC curves corresponding to the E<sup>rns</sup>, tE2 and NS3 were all more than 0.98. The values that achieved the best relationship between diagnostic sensitivity and specificity were selected as the cut-off value of each ELISA. The corresponding sensitivities to E<sup>rns</sup>, tE2 and NS3 were 96%, 98.5% and 96% while the specificities were 95.3%, 93.7% and 93.7%, respectively (Table. 2).

When all the parameters of each ELISA were established, the assays developed were applied to the testing of 201 positive serum samples of vaccinated pigs and 64 negative serum samples of unvaccinated piglets, previously characterized by the virus neutralization assay. The three assays showed high levels of sensitivity and specificity when compared with the reference test. ELISA-E2 data showed that 4 out of 64 serum samples of unvaccinated piglets were

Table 2. Sensitivity (Se) and specificity (Sp) values estimated for the ELISA tests based on E<sup>rns</sup>, tE2 and NS3 recombinant antigens using ROC curve by SPSS version 15.0

	E <sup>rns</sup>	tE2	NS3
Cut-off value	0.258	0.165	0.167
Se (%)	96	98.5	96
Sp (%)	95.3	93.7	93.7

positive and 3 out of 201 positive samples of vaccinated pigs were negative (Fig. 2B). For the ELISA-E<sup>rns</sup>, 3 out of 64 negative samples showed ELISA-E<sup>rns</sup> values above the established cut-off point and 8 out of 201 positive samples showed values below that point (Fig. 2A). Similarly, for ELISA-NS3 with a cut-off value set to 0.167, 4 out of 64 negative




Fig. 2. The multiple ELISAs developed with the recombinant E<sup>ms</sup> (A), tE2 (B) or NS3 (C) antigen. A total of 64 negative serum samples and 201 positive serum samples, which were characterized by virus neutralization assay, were applied to each ELISA. Each sample was tested in duplicate and the corresponding result was expressed as the OD<sub>492nm</sub> value obtained with the recombinant antigen (E<sup>ms</sup>, tE2 or NS3). The optimum cut-off value determined by ROC analysis is indicated by a broken horizontal line.



Table 3. Intra- and Inter-assay variation coefficient (CV) estimated for the ELISA tests based on E<sup>rns</sup>, tE2 and NS3 recombinant antigens

	$E^{\text{rms}}$	tE2	NS3
Intra-assay CV	4.23%	2.89%	3.32%
Inter-assay CV	11.5%	9.13%	11.19%

Variation coefficients (VC: standard deviation of replicates/ mean of replicates) correspond to the raw absorbance of the positive control sample in six replicates run in the same plate and in different plates.

samples showed higher and 8 out of 201 serum samples of vaccinated pigs were lower than the established cut-off point (Fig. 2C). Virus neutralization assay demonstrated that no CSFV neutralizing antibodies in sera of all unvaccinated piglets were detected. The CSFV neutralizing antibodies were positive in sera of all vaccinated pigs. The variation analysis indicated that both intra- and inter-assay VCs were lower than 15% for raw absorbance values (Table.3), suggesting adequate reproducibility and repeatability of the ELISAs.

# E<sup>rns</sup>, E2 and NS3 antibody responses in pigs vaccinated with the C-strain

To investigate E<sup>rns</sup>, E2 and NS3 antibody responses in pigs, specific antibodies in 90 sera of vaccinated pigs were measured separately at 1, 3 and 5 months p.v. The data showed that a single dose of vaccination induced the specific anti-E<sup>rns</sup>, anti-E2 and anti-NS3 responses in sera of pigs at 1<sup>st</sup> month p.v. and there was no significant difference of antibody titers between the 1<sup>st</sup> and 5<sup>th</sup> month p.v. (Fig. 3). The results demonstrated that a single vaccination with C-strain can confer anti-CSFV humoral responses lasting at least 5 months, which further confirmed the results previously reported<sup>[28]</sup>.




Fig. 3. Antibody responses of vaccinated pigs to  $E^{rns}$ , E2 and NS3 detected by the multiple ELISAs. Ninety serum samples from vaccinated pigs at 1, 3, or 5 months p.v. were analyzed for reactivity with immobilized  $E^{rns}$ , tE2 and NS3, using the optimized conditions as described in the text. Mean  $OD_{492nm}$  values are represented as a solid line.

#### DISCUSSION

Antibodies against E<sup>rns</sup>, E2 and NS3 are measured in sera of pigs are common indicators of infection with CSFV. Detection of specific E<sup>rns</sup> or E2 antibodies has widely been used for diagnosis and surveillance of CSF diseases. E<sup>rns</sup>, E2 and NS3 of Pestiviruses have been expressed in baculovirus/insect cells or E. coli, and used as diagnostic antigens<sup>[6, 13, 29]</sup>. ELISA based on the recombinant E<sup>rns</sup>, E2 or chimeric E<sup>rns</sup>/E2 antigen has been developed for detection of CSFV infection<sup>[4, 12, 14]</sup>. In BVDV, multiple ELISAs based on recombinant E<sup>rns</sup>, E2 and NS3 antigens have been developed and applied to determine the pattern of anti-BVDV antibodies in bovine serum samples<sup>[2]</sup>. The E2 subunit or inactivated BVDV vaccine exhibits properties of the "marker vaccines" when an appropriated ELISA based on NS3 is applied<sup>[1, 16]</sup>. However, in CSFV, development of ELISA-NS3 or multiple ELISAs have not been reported. Our previous results demonstrated that the CSFV Erns and NS3 expressed in eukaryotic or prokaryotic expression



system revealed bioactivity<sup>[15, 32]</sup>. In this study the E<sup>rns</sup>, tE2 and NS3 proteins of CSFV were expressed from E. coli. Western blotting indicated that three proteins expressed from E. coli could be reactive with anti-E2 monoclonal antibody and anti-CSFV polyclonal antibody. Because of hydrophobic amino acids and rare codons, the full-length E2 has a lower expression level in E.coli. By removing the C-terminal domain and fusing the N-terminal part of E2 with maltose-binding protein (MBP), a high expression level of the tE2 was obtained in strain BL21 CondonPlus (DE3)-RIL. Because the proteins were expressed mainly in the form of inclusion bodies, we also purified the recombinant E<sup>rns</sup>, tE2 and NS3 by SDS-PAGE separation and gel recovery. Western blotting confirmed that the purified proteins exhibited reactivity with specific anti-CSFV antibody (data not shown), which could be a simple, useful method for laboratory preparation of recombinant protein antigens.

Different methods were applied to determine the optimal cut-off value for ELISA. The negative mean plus three standard deviations (X<sub>neg</sub>+3σ) is the traditional cut-off value<sup>[25]</sup>. In the X<sub>neg</sub>+3σ determined point, the cut-off values corresponding to ELISA-E<sup>rms</sup>, ELISA-E2 and ELISA-NS3 are 0.301, 0.186 and 0.183, respectively. When the cut-off values are considered, the sensitivities of the ELISA-E<sup>rms</sup>, ELISA-E2 and ELISA-NS3 are 95%, 94.5% and 95.5%, while the specificities are 95.3%, 95.3% and 93.7%, respectively. In the multiple ELISAs described, the cut-off values were determined by ROC analysis. Based on the cut-off values established from these two methods, the multiple ELISAs are specific, sensitive and reproducible. Multiple ELISA data revealed that

several negative serum samples of unvaccinated piglets showed values above the cut-off point and that some positive serum samples of vaccinated pigs exhibited values below the cut-off point. For the former, a possible explanation is that the multiple ELISAs are sensitive enough to test the low levels of maternal antibodies. For the latter, it is could be due to low serum neutralization activity plus subjective plaque-reading or to deviation in the ELISA. By Western blotting, the reactivity of positive sera measured by ELISAs with the recombinant E<sup>rns</sup>, E2 and NS3 proteins were further confirmed and their consistency was observed. These results suggested the multiple ELISAs developed were effective and accurate for detection of specific antibodies in pig sera. Furthermore, the ELISA-E<sup>rns</sup> and ELISA-NS3 should be of particular interest since they could be used to detect the presence of specific antibodies (directed to E<sup>rns</sup> and NS3) that were not detectable by the virus neutralization assay with CSFV. Thus, the inclusion of E<sup>rns</sup> and NS3 would extend the range of antibodies that can be detected in comparison with E2 alone.

To evaluate the pattern of anti-CSFV antibodies p.v. with C-strain vaccine, specific anti-E<sup>ms</sup>, anti-E2 or anti-NS3 antibody titers in sera of vaccinated pigs were tested by the multiple ELISAs. Data showed that there is no significant difference of the antibody titers in sera of vaccinated pigs between 1<sup>st</sup> and 5<sup>th</sup> month p.v. with a single vaccination. However, the OD<sub>492</sub> values of ELISA-E2 were lower in comparison with that of ELISA-E<sup>rns</sup> and ELISA-NS3. A possible explanation is that the truncated E2 protein from the prokaryotic expression system was employed as an ELISA coating antigen. Currently, a blocking ELISA based on the recombinant truncated E2 of BVDV has



been developed. Importantly, the blocking ELISA measures avidity of BVDV-specific immunoglobulins as an alternative to the classic virus neutralization assay and can discriminate between infected and vaccinated animals<sup>[8]</sup>. The multiple ELISAs described here do not require the manipulation of infectious material, and simultaneous application of the three assays allows the detection of anti-CSFV antibodies in pig sera by a simple, rapid and secure methodology, so that the assays represent a valuable tool for the detection of CSFV infection and serological survey in CSFV-free countries or for the evaluation of the efficacies of live attenuated CSFV vaccines.

#### Acknowledgements

We were grateful to Dr. E. Weiland for kindly providing CSFV E2 mAb. This work was supported by the National Natural Science Foundation of China (30771597) and by the Key Project of Science and Technology of Wuhan (200720422141).

#### References

- Bouma A, de Smit A J, de Kluijver E P, et al. 1999. Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus. Vet Microbiol, 66: 101-114.
- 2 Chimeno Zoth S, Taboga O. 2006. Multiple recombinant ELISA for the detection of bovine viral diarrhoea virus antibodies in cattle sera. J Virol Methods, 138: 99-108.
- 3 Clavijo A L M, Riva J, Mallory M, *et al.* 2001.

  Development of a competitive ELISA using a truncated E2 recombinant protein as antigen for detection of antibodies to classical swine fever virus. **Res Vet Sci.** 70: 1-7.
- 4 Colijn E O, Bloemraad M, Wensvoort G. 1997. An improved ELISA for the detection of serum antibodies directed against classical swine fever virus. Vet Microbiol, 59: 15-25.
- 5 De Smit A J. 2000. Laboratory diagnosis, epizootiology, and efficacy of marker vaccines in classical swine fever: a

- review. Vet Q, 22: 182-188.
- 6 Deregt D, Dubovi E J, Jolley M E, et al. 2005. Mapping of two antigenic domains on the NS3 protein of the pestivirus bovine viral diarrhea virus. Vet Microbiol, 108: 13-22.
- 7 Edwards S, Fukusho A, Lefevre P C, et al. 2000. Classical swine fever: the global situation. Vet Microbiol, 73: 103-119.
- 8 Franco Mahecha O L, Ogas Castells M L, Combessies G, et al. 2011. Single dilution Avidity-Blocking ELISA as an alternative to the Bovine Viral Diarrhea Virus neutralization test. J Virol Methods, 175: 228-235.
- 9 Hulst M M, Westra D F, Wensvoort G, et al. 1993. Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera. J Virol, 67: 5435-5442.
- 10 Jacobson R H. 1998. Validation of serological assays for diagnosis of infectious diseases. Rev Sci Tech, 17: 469-526.
- 11 Konig M, Lengsfeld T, Pauly T, et al. 1995. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. J Virol, 69: 6479-6486.
- 12 Langedijk J P, Middel W G, Meloen R H, *et al.* 2001. Enzyme-linked immunosorbent assay using a virus type-specific peptide based on a subdomain of envelope protein E(rns) for serologic diagnosis of pestivirus infections in swine. J Clin Microbiol, 39: 906-912.
- 13 Lin M, Trottier E, Mallory M. 2005a. Enzyme-linked immunosorbent assay based on a chimeric antigen bearing antigenic regions of structural proteins Erns and E2 for serodiagnosis of classical swine fever virus infection. Clin Diagn Lab Immunol, 12: 877-881.
- 14 Lin M, Trottier E, Mallory M. 2005. Enzyme-linked immunosorbent assay based on a chimeric antigen bearing antigenic regions of structural proteins Erns and E2 for serodiagnosis of classical swine fever virus infection. Clin Diagn Lab Immunol, 12: 877-881.
- 15 Luo X, Ling D, Li T, et al. 2009. Classical swine fever virus Erns glycoprotein antagonizes induction of interferon-beta by double-stranded RNA. Can J Microbiol, 55: 698-704.
- 16 Makoschey B, Sonnemans D, Bielsa J M, et al. 2007. Evaluation of the induction of NS3 specific BVDV



antibodies using a commercial inactivated BVDV vaccine in immunization and challenge trials. **Vaccine**, 25: 6140-6145.

- 17 Meuwissen M P, Horst S H, Huirne R B, et al. 1999. A model to estimate the financial consequences of classical swine fever outbreaks: principles and outcomes. Prev Vet Med, 42: 249-270.
- 18 Moennig V. 2000. Introduction to classical swine fever: virus, disease and control policy. Vet Microbiol, 73: 93-102.
- 19 Moennig V, Plagemann P G. 1992. The pestiviruses. Adv Virus Res, 41: 53-98.
- 20 Moormann R J, BoumaA, Kramps J A, et al. 2000. Development of a classical swine fever subunit marker vaccine and companion diagnostic test. Vet Microbiol, 73: 209-219.
- 21 Morrin F, Wilson B, Conner M. 1997. Evaluation of an immuno-peroxidase monolayer assay for detection of pestivirus antibodies in pigs. Vet J, 50: 294-299.
- 22 Moser C, Ruggli N, Tratschin J D, et al. 1996. Detection of antibodies against classical swine fever virus in swine sera by indirect ELISA using recombinant envelope glycoprotein E2. Vet Microbiol, 51: 41-53.
- 23 Paton D J, Ibata G, Edwards S, et al. 1991. An ELISA detecting antibody to conserved pestivirus epitopes. J Virol Methods, 31: 315-324.
- 24 Stegeman A, Elbers A, de Smit H, et al. 2000. The 1997-1998 epidemic of classical swine fever in the Netherlands. Vet Microbiol, 73: 183-196.
- 25 Sutula C, Gillett J, Morrissey S, et al. 1986. Interpreting

- ELISA data and establishing the positive–negative threshold. **Plant Dis,** 8: 722-726.
- 26 Terpstra C, Bloemraad M, Gielkens A L. 1984. The neutralizing peroxidase-linked assay for detection of antibody against swine fever virus. Vet Microbiol, 9: 113-120.
- 27 Thiel H J, Stark R, Weiland E, et al. 1991. Hog cholera virus: molecular composition of virions from a pestivirus. J Virol, 65: 4705-4712.
- 28 Van Oirschot J T. 2003. Vaccinology of classical swine fever: from lab to field. Vet Microbiol, 96: 367-384.
- 29 Van Rijn P A, Bossers A, Wensvoort G, et al. 1996. Classical swine fever virus (CSFV) envelope glycoprotein E2 containing one structural antigenic unit protects pigs from lethal CSFV challenge. J Gen Virol, 77:2737-2745.
- 30 Wan C, Yi L, Yang Z, et al. 2010. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Vet Immunol Immunopathol, 137: 47-53.
- 31 Wang Y, Wang Q, Lu X, *et al.* 2008. 12-nt insertion in 3' untranslated region leads to attenuation of classic swine fever virus and protects host against lethal challenge. Virology, 374:390-398.
- 32 Weiland E, Ahl R, Stark R, et al. 1992. A second envelope glycoprotein mediates neutralization of a pestivirus, hog cholera virus. J Virol, 66: 3677-3682.
- 33 Wen G, Chen C, Luo X, et al. 2007. Identification and characterization of the NTPase activity of classical swine fever virus (CSFV) nonstructural protein 3 (NS3) expressed in bacteria. Arch Virol, 152: 1565-1573.

